Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non–small cell lung cancer

…, D Owen, Y Toi, P Walker, GA Otterson, SH Patel… - JAMA …, 2020 - jamanetwork.com
Importance The spectrum of individual immune-related adverse events (irAEs) from anti–programmed
cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) immune …

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global …

…, M Hafiz, A De Giglio, M Muzaffar, SH Patel… - Cancer Immunology …, 2020 - Springer
Background Immune-related adverse events (irAEs) comprise a distinct spectrum of auto-inflammatory
manifestations triggered due to immune checkpoint inhibitors (ICI). Current data …

[HTML][HTML] Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant …

…, M Husain, JS Bassett, L Wang, G Tinoco, SH Patel… - BMC cancer, 2020 - Springer
Background The microbiome has been shown to affect the response to Immune Checkpoint
Inhibitors (ICIs) in a small number of cancers and in preclinical models. Here, we sought to …

Smallholder wood production and population pressure in East Africa: evidence of an environmental Kuznets curve?

SH Patel, TC Pinckney, WK Jaeger - Land Economics, 1995 - JSTOR
The incentives for growing fuelwood on small farms are examined using survey data from
Kenya. The analysis finds that tree planting is a competitive activity and that farmers are …

[HTML][HTML] Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival

TC Haddad, S Zhao, M Li, SH Patel, A Johns… - Cancer Immunology …, 2022 - Springer
Introduction Immune checkpoint inhibitors (ICI) are associated with unique immune-related
adverse events (irAEs). Immune-related thrombocytopenia (irTCP) is an understudied and …

Graduate students' ownership and attribution rights in intellectual property

SH Patel - Ind. LJ, 1995 - HeinOnline
University intellectual property policies have become standard form policies varying only
slightly in substance from one university to another. At their core, these policies provide …

[HTML][HTML] Serum albumin: early prognostic marker of benefit for immune checkpoint inhibitor monotherapy but not chemoimmunotherapy

Y Guo, L Wei, SH Patel, G Lopez, M Grogan, M Li… - Clinical lung cancer, 2022 - Elsevier
MicroAbstract Serum albumin in cancer patients is associated with clinical outcomes. In a
single-center retrospective study of 210 advanced NSCLC patients receiving immune …

Increased bleeding risk associated with concurrent vascular endothelial growth factor receptor tyrosine kinase inhibitors and low‐molecular‐weight heparin

SH Patel, TL George, TF Wang, SM Vogt, E Folefac… - Cancer, 2021 - Wiley Online Library
Background Some cancer patients who are diagnosed with thromboembolism may require
dual treatment with vascular endothelial growth factor receptor (VEGFR) tyrosine kinase …

Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer

M Li, D Spakowicz, S Zhao, SH Patel, A Johns… - Cancer Immunology …, 2020 - Springer
Background Checkpoint inhibitor pneumonitis (CIP) is an immune-related adverse event that
may complicate treatment with immune checkpoint inhibitors (ICI) and can cause significant …

Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events

…, GA Otterson, CJ Presley, K Kendra, SH Patel… - Cancer Immunology …, 2021 - Springer
Background The aim of this retrospective study was to demonstrate that irAEs, specifically
gastrointestinal and pulmonary, examined through International Classification of Disease (ICD…